Walla Al-Hertani
Clinical Genetics (M.D.) · Orange, CANPI 1104395656
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Sanofi accounts for 63.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $35,248 and has fallen 83.3% since, to $5,886 in 2025. Among clinical genetics (m.d.) clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1215.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$38K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Amicus Therapeutics, Inc.$4K
- Zevra Therapeutics Inc$2K
- Intrabio Inc$2K
- Travere Therapeutics, Inc.$47
- plus $98 from 3 others
Across 32 payments — averaging $11,831 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$140K
- Sanofi$116K
- Ultragenyx Pharmaceutical Inc.$101K
- Chiesi USA, Inc.$22K
What the payments were for
- Consulting fees$33,76856%
- Speaking & faculty fees$9,85216%
- Travel & lodging$16,14027%
- Food & beverage$9582%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 27 | $38,363 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $14,430 |
| Amicus Therapeutics, Inc. | 4 | $4,435 |
| Zevra Therapeutics Inc | 1 | $1,749 |
| Intrabio Inc | 2 | $1,672 |
| Travere Therapeutics, Inc. | 8 | $47 |
| Chiesi USA, Inc. | 1 | $42 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,794 in reported general payments places this provider in the 90th percentile of 91 clinical genetics (m.d.) providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RavictiGlycerol Phenylbutyrate | 11 | $1,068,411 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in Orange
- John GargusOrange$124K
- Virginia KimonisOrange$79K
- Albert la SpadaOrange$2K
- Elizabeth ChaoOrange$1K
- Changrui XiaoOrange$540
- Fuki HisamaOrange$214
- June-Anne GoldOrange$117
- Nicola LongoLos Angeles$295K
- Jose CamachoSan Francisco$126K
- John CroninWoodside$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.